Melanoma-specific survival and relapse-free survival are significantly improved for tumors with high tumor mutational burden and BRAF V600 mutation – results of 83 stage IIIC-IV patients with adjuvant anti-PD-1 therapy
2025 · EJC Skin Cancer · 0 citations
https://doi.org/10.1016/j.ejcskn.2025.100360